HC Wainwright Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $270.00

Palvella Therapeutics (NASDAQ:PVLA) had its target price hoisted by equities research analysts at HC Wainwright from $255.00 to $270.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 134.25% from the stock’s previous close.

A number of other brokerages also recently commented on PVLA. Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. BTIG Research lifted their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. UBS Group restated a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. Finally, Craig Hallum initiated coverage on Palvella Therapeutics in a research report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $185.87.

Palvella Therapeutics Stock Down 1.5%

NASDAQ:PVLA traded down $1.78 during trading hours on Tuesday, reaching $115.26. 49,541 shares of the company’s stock were exchanged, compared to its average volume of 311,983. The company has a market capitalization of $1.36 billion, a P/E ratio of -44.00 and a beta of -0.31. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18. The business’s 50-day simple moving average is $103.44 and its two-hundred day simple moving average is $89.12.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares of the company’s stock, valued at approximately $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The disclosure for this sale is available in the SEC filing. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Suvretta Capital Management LLC lifted its stake in Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after acquiring an additional 70,000 shares in the last quarter. Frazier Life Sciences Management L.P. grew its stake in Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after acquiring an additional 32,388 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 30.9% in the 4th quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock valued at $74,226,000 after purchasing an additional 167,597 shares during the period. Vanguard Group Inc. increased its holdings in shares of Palvella Therapeutics by 13.3% in the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after purchasing an additional 65,960 shares during the period. Finally, State Street Corp lifted its position in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares in the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.